Kornimate/medical-research-clean huggingface dataset:
the validity of the use of imaging in cervical cancer staging

Conditions: Cervical Cancer Stage, Imaging Modalities

Summary: the study wil aim to investigate the accuracy of imaging in the staging of women diagnosed with cervical cancer

patients with cervical cancer undergoing surgery will also undergo pet-ct scan, ct scan, trans-abdominal ultrasound of the pelvis and abdomen to assess pelvic and para-aortic lymph node status, mri and trans-vaginal ultrasound (tvus) to assess tumour size and parametrial infiltration. as per the current unit protocol, patients will be assessed clinically for operability. the performance of the different imaging modalities will be measured against the histological status of the parametric and lymph nodes and tumour size as measured by the pathologists. ct, pet-ct, mri and abdominal ultrasound will be reported as per the usual departmental process. staff in the radiology department will be blinded for the different imaging modalities performed. tvus will be performed in the unit by different gynaecological oncologists and fellows and at the time of the investigation will be blinded with regards to clinical findings and the reports of other imaging studies performed. the sensitivity, specificity, positive and negative predictive values will be calculated for the different imaging modalities.

Eligibility criteria:
inclusion criteria: - women diagnosed with cervical cancer able and willing to provide informed consent exclusion criteria: previously treated for cervical cancer unable to provide informed consent patients with contra-indications to undergo surgical treatment -

Keywords: cervical cancer ultrasound mri ct scan pet-ct scan
characteristics and dynamics of tcr repertoire in patients with hematological malignancies after allo-hsct

Conditions: Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Graft Vs Host Disease; Recurrence

Summary: graft-versus-host disease (gvhd) and relapse, which is mainly due to lack of graft-versus-leukemia (gvl), are the most frequent and severe complications of allogeneic hematopoietic stem cell transplantation (allo-hsct). t cells expanded from mature t cells in the graft play a dominant role in development of gvhd and gvl early after allo-hsct. recent applications of high-throughput sequencing (hts) to the t cells repertoire open a new avenue for us to look deeply into how these t cells dynamically adjust in the context of the recipient's environment. the main goal of this research study is to set up a mathematical model based on t cell receptor (tcr) sequencing to enable prediction for the key immunologic outcomes early post-transplantation. this study will deepen the understanding of the molecular mechanisms driving the most deadly post-transplantation complications, and serve as convincing evidence upon which to choose a better donor and a more proper transplantation approach. this observational trial will perform hts for tcr β-chain complementarity determining region 3 (cdr3) repertoires of grafts and peripheral blood samples from recipients post-transplantation and analyze the relationship between dynamics of tcr cdr3 repertoires and clinical outcomes early post-transplantation, especially including gvhd and relapse. the investigators want to know how the antigen environment in recipients drives dynamics of mature t cells from grafts in order to use the new discovered rules to better predict and treat the disease process.


Eligibility criteria:
inclusion criteria: 1. patients with aml, all, mds, undergone myeloablative hematopoietic stem cell transplantation about 1 year ago. 2. patients who have residual peripheral blood mononuclear cell samples freezed up to now which had been disposed at the time of about 1-month, 2-month after allo-hsct. 3. patients whose residual grafts have been freezed up to now. exclusion criteria: 1. patients whose grafts or residual peripheral blood mononuclear cell samples are failed to be thawed. 2. patients whose samples are failed with rna extraction. 3. patients whose rna sequencing are failed. 4. patients who died within 2 months after allo-hsct.

Keywords: tcr repertoire next generation sequencing all aml mds myeloablative
a phase ii study of shr2554 in patients with relapsed or refractory follicular lymphoma

Conditions: Follicular Lymphoma

Summary: the study is being conducted to evaluate the efficacy and safety of shr2554 in patients with relapsed or refractory follicular lymphoma


Eligibility criteria:
inclusion criteria: 1. males or females aged ≥18 years 2. histologically confirmed follicular lymphoma 3. eastern cooperative oncology group performance status (ecog ps) score ≤2 4. life expectancy ≥ 12 weeks 5. treated with cd20 antibody, refractory to or relapse from prior anti-cancer therapies 6. have measurable lesions 7. the subject is willing and able to comply with the visit schedule, dosing schedule, laboratory tests, and other clinical study procedures exclusion criteria: 1. have been treated with a compound of the same machanism; 2. accompanied by central nervous system infiltration; 3. received autologous stem cell transplantation within 60 days before signing the agreement, and received allogeneic stem cell transplantation or car-t therapy within 90 days; 4. underwent major surgery or experienced severe trauma within 4 weeks prior to the first dose of the investigational drug 5. known active infection 6. history of clinically severe cardiovascular diseases 7. have other malignancies within 5 years prior to screening pregnant or lactating women 8. the subject is unable to swallow, or has a history of active gastrointestinal inflammation, chronic diarrhea, known diverticulosis, or a history of gastrectomy or gastric banding that affects drug absorption. 9. the subject is taking a known medium or strong cyp inducer. 10. based on the investigator's judgment, there are objective conditions that may prevent the subject from completing the study as planned or the subject has other factors, concomitant diseases, concomitant treatments, or abnormal laboratory findings that may lead to early study termination
a study assessing efficacy of brivaracetam in subjects with persistent pain after shingles (post-herpetic neuralgia)

Conditions: Neuralgia, Postherpetic

Summary: study will assess efficacy, safety and tolerability of brivaracetam in post-herpetic neuralgia (phn). duration of 7 weeks divided into 3 periods with no up-titration, nor down-titration.


Eligibility criteria:
inclusion criteria: inclusion criteria: * male/female subject aged 18 years or older. * pain present for at least 6 months after healing of the acute herpes zoster skin rash. * pain intensity score assessed on an 11-point numerical pain rating scale with a score of at least 4 at the screening visit and with an average weekly score of at least 4 on an 11-point numerical pain rating scale during baseline period. exclusion criteria: * subject getting any kind of psychological support to help cope with pain such as biofeedback or behavioral cognitive therapy. * subject who had undergone or who is scheduled for neurolytic or neurosurgical therapy for post-herpetic neuralgia (phn) or who receives trans-electrical neural stimulation (tens. * tricyclic antidepressants (tcas) or non-steroidal anti-inflammatory drug (nsaids) or permitted opioid analgesics ('strong' opioids are forbidden) that started less than 30 days and/or are not stabilized prior to screening and/or are not expected to be kept stable during the study. * intake of more than two pain treatments at trial entry (screening visit) including tricyclic antidepressants (tcas), non-steroidal anti-inflammatory drugs (nsaids) or permitted opioid analgesics. * subject being treated with carbamazepine for any indication. * known coexistent source of painful peripheral neuropathy or other systemic disease associated with a secondary painful neuropathy. * subject being treated in the four weeks prior to screening visit with 'strong' opioid analgesics. exclusion criteria:

Keywords: post-herpetic neuralgia (phn) brivaracetam
oxytocin's effect on social pain empathy

Conditions: Healthy

Summary: the aim of the present experiment is to examine oxytocin's behavioral and neural effects on social pain empathy

in the current study, the investigators plan to examine whether oxytocin modulates behavior and neural activity during observing another person being excluded in an online ball-tossing game (a modified cyberball paradigm).

Eligibility criteria:
inclusion criteria: * healthy participants without past or current psychiatric or neurological disorders exclusion criteria: * history of head injury * medical or psychiatric illness * smoking or drinking 24 hours before experiment

Keywords: oxytocin social cognition fmri empathy
verification of predictive biomarkers for pancreatic cancer treatment using multicenter liquid biopsy

Conditions: Pancreas Adenocarcinoma

Summary: this study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.

clinical applicability of kras mutations using circulating-tumor dna in pancreatic cancer patients. * quantification and monitoring of kras mutations using droplet digital pcr in ctdna extracted from collected patient samples. * correlation analysis of kras mutation results with clinical data. discovery of biomarkers for predicting pancreatic cancer prognosis through ctdna panel. * gene panel composition for pancreatic cancer therapeutic target determination and monitoring. * a panel was performed using gdna and ctdna of tumor tissue collected from pancreatic cancer patients. * comparative analysis of panel results and quantitative kras mutations and evaluation of clinical applicability.

Eligibility criteria:
inclusion criteria: * patients with pathologically confirmed pancreatic adenocarcinoma. exclusion criteria: * patients disagree with the study.

Keywords: pancreas adenocarcinoma circulating-tumor dna kras mutations cancer panel prognostic markers
the effect of an anti-obesity drug, semaglutide, as treatment in new-onset idiopathic intracranial hypertension (iih) compared to standard weight management (dietician) with regards to change in weight and intracranial pressure

Conditions: Idiopathic Intracranial Hypertension; Intracranial Pressure; Obesity; Pseudotumor Cerebri Syndrome; Papilledema; Weight Loss

Summary: 50 patients with verified new-onset idiopathic intracranial hypertension are randomly allocated to standard weight management (dietician counselling) or trial intervention consisting of subcutaneous injections with semaglutide for 10 months combined, in the initial 8 weeks following diagnosis, with a very low calorie-diet (max 800 kcal/day)

idiopathic intracranial hypertension is primarily observed in obese female and weight management promotes disease control by yet unsettled mechanisms. effective, fast and lasting weight loss is crucial, however, hard to achieve. current weight management strategy in iih in denmark is counselling by a dietician. this study investigates whether an initial very low calorie diet (max 800 kcal/day) for 8 weeks following the diagnosis combined with glp1-ra treatment throughout 10 months is tolerated and more efficient in achieving substantial weight loss and reduction of intracranial pressure. furthermore, a number of secondary outcomes are measured including headache burden, quality of life, structure and function of the optic nerve, non-invasive surrogate markers of intracranial pressure, body fat mass, bone health, fatty liver disease and a range of cerebrospinal-, blood- and urine markers of i.a. the hormonal, inflammatory, metabolic, and headache biomarker profile. the intervention may candidate as a future first-line treatment regime.

Eligibility criteria:
inclusion criteria: * confirmed new onset definite iih with papilledema and lumbar opening pressure ≥25 cm cerebrospinal fluid according to friedmann diagnostic criteria * bmi ≥ 27 * use of contraceptive methods with failure rates of less than 1 % throughout the study period for group a and for at least an additional 2 months after cessation of semaglutide * written, informed consent exclusion criteria: * unable to provide written informed consent or participate * malignant iih with visual threat that requires surgical intervention, i.e., cerebrospinal fluid diversion (shunting), optic nerve sheet fenestration or cerebral venous sinus stenting * pregnancy or breastfeeding * treatment with antidiabetics, blood-thinners or medication that may increase the risk of adverse events * diabetes, congestive heart failure, severe vascular disease, pancreatitis, severe ophthalmological disorders other than iih (e.g. retinopathy) * history or family history of thyroid carcinomas or multiple endocrine neoplasias (men1/men2) * history of bariatric surgery * known hypersensitivity to any contents of semaglutide® * other severe/uncontrolled mental or physical disease

Keywords: idiopathic intracranial hypertension papilledema weight loss obesity pseudotumor cerebri syndrome intracranial pressure
renal arterial resistive index as a noninvasive biomarker of disease activity in lupus nephritis patients

Conditions: Lupus Nephritis

Summary: systemic lupus erthymatosous (sle) is achronic inflammatory multi system auto immue disease characterized by pathogenic auto anti bodies production against nuclear structures (bolouri et al.,2022), sle affecting mainly woemn of childbearing age and is chracterized by unpredictable flares and remissions , disease variety varied from mild episode disorder to arpidly progressive life -threatening illness.. ln is diagnosed by either the presence of proteinuria \>0.5g/day. active urinary sediment , or an unexplained rise in serum creatinine there fore , identifying new invasive biomarkers of ln severity and outcome is mandatory, renal arterial resistive index ( rri) is anon invasive biomarker that has been studied as apotential indicator of disease activity in ln patients.


Eligibility criteria:
inclusion criteria: * aged ≥18 years. * sle patients fulfilling the sle international collaborating clinics (slicc) classification criteria and matched controls. * patients cooperative and can answer questions. * patients who are able and willing to give written informed consent. exclusion criteria: * • individuals with other autoimmune diseases. * diabetes. * hypertension. * heart failure. * hepatic diseases. * chronic renal failure. * renal artery stenosis. * renal vein thrombosis. * intrarenal arteriovenous fistula. * obstructive nephropathy. * urinary tract obstruction that could affect ri of intra renal arteries. * un cooperative patients. * patients not able and willing to give written informed consent.
study of the effect of cp-751,871 in combination with gemcitabine and cisplatin in patients with advanced non-small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: gemcitabine and cisplatin given together is a standard treatment option for advanced lung cancer patients. the purpose of this study is to assess if the life span is longer in patients taking the investigational drug cp-751,871 in combination with gemcitabine and cisplatin compared to gemcitabine and cisplatin alone. considering a 10% rate of drop-outs, 1,210 participants will be required in order to have an adequate sample size (1,100 evaluable patients) and power to detect a 30% prolongation of survival on the experimental arm.


Eligibility criteria:
inclusion criteria: * non-small cell lung cancer (nsclc), advanced, chemotherapy-naive * male or female \> 18 years * eastern oncology cooperative group (ecog) performance status (ps) 0 or 1 * adequate organ function exclusion criteria: * uncontrolled hypertension or diabetes; * pregnant female; * symptomatic central nervous system (cns) metastasis, requirement for chronic corticosteroids.
efficacy and safety study of talimogene laherparepvec compared to granulocyte macrophage colony stimulating factor (gm-csf) in melanoma

Conditions: Melanoma

Summary: the objective of this study is to evaluate the efficacy and safety of treatment with talimogene laherparepvec compared to subcutaneously administered gm-csf in patients with unresectable stage iiib, iiic and stage iv melanoma. the efficacy endpoints of the study aim to demonstrate overall clinical benefit for patients treated with talimogene laherparepvec as compared to gm-csf.


Eligibility criteria:
inclusion criteria: * males or females age ≥ 18 years * stage iiib, iiic or stage iv disease that is not surgically resectable * injectable disease (i.e. suitable for direct injection or through the use of ultrasound guidance) * at least 1 injectable cutaneous, subcutaneous or nodal melanoma lesion \>= 10 mm in longest diameter or, multiple injectable melanoma lesions which in aggregate have a longest diameter of \>= 10 mm * serum lactate dehydrogenase (ldh) levels less than 1.5 x upper limit of normal (uln) * eastern cooperative oncology group (ecog) performance status of 0 or 1 * prolongation in international normalized ratio (inr), prothrombin time (pt), and partial thromboplastin time (ptt) when the result is from therapeutic anticoagulation treatment are permitted for patients whose injectable lesions are cutaneous and/or subcutaneous such that direct pressure could be applied in the event of excessive bleeding exclusion criteria: * clinically active cerebral or any bone metastases. patients with up to 3 (neurological performance status of 0) cerebral metastases may be enrolled, provided that all lesions have been adequately treated with stereotactic radiation therapy, craniotomy, gammaknife therapy, with no evidence of progression, and have not required steroids, for at least two (2) months prior to randomization * greater than 3 visceral metastases (this does not include lung metastases or nodal metastases associated with visceral organs). for patients with \ 3 cm, and liver lesions must meet response evaluation criteria in solid tumors (recist) criteria for stable disease for at least 1 month prior to randomization

Keywords: melanoma oncovex^gm-csf gm-csf stage iiib, iiic and iv disease oncolytic oncovex t-vec talimogene laherparepvec
impact of music intervention on pain control in first trimester surgical abortion under local anesthesia

Conditions: First Trimester Abortion; Surgical Abortion; Music Intervention; Local Anesthesia; Pain

Summary: a surgical abortion under local anesthesia is potentially painful. a protocol using analgetic is systematically used. also the protocol is relevant , the question of taking care of the pain in a safe manner remains. the use of music during surgery can have a real effect on pain and anxiety. this study has for goal to evalued the use of music on pain as adjuvant treatement instead of a standard care for an abortion.

a surgical abortion under local anesthesiac is potentially painful. a protocol using analgetic is systematically used. also the protocol is relevant, the question of taking care of the pain in a safe manner remains. the use of music during surgery can have a real effect on pain and anxiety. this study has for goal to evalued the use of music on pain as adjuvant treatment instead of a standard care for an abortion. the number of patients needed is estimate to be eighty patients per group. the result of the study could allow : * showing the effectiveness of music intervention before operative abortion as adjuvant treatment on the pain, anxiety and nausea during a surgical abortion by suction aspiration under local anesthesia. * improving the experience of an abortion and the satisfaction of the patients as well as lowering the use of drugs.

Eligibility criteria:
inclusion criteria: * every patients must have more than 18 years old * hospitalised at the angers hospital for a surgical abortion under local anesthesia. * affiliated or be part of the french sécurité sociale ( health service ) * to have signed a consent form exclusion criteria: * patients not speaking french * people who should not use music intervention ( total or partial hearing difficulties) * no consent given * adults protected by the law * not being part of another medical study

Keywords: first trimester abortion surgical abortion music intervention local anesthesia pain
korea osimertinib real world evidence study to assess safety and efficacy - plus

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: this is a local, prospective, non-interventional, regulatory postmarketing surveillance study. the objectives of this study are to assess the safety and efficacy of single agent tagrisso (osimertinib, hereinafter "the study drug") in a real world setting according to the approved label in korea.

* primary objective: to assess safety of the tagrisso for patients with nsclc treated with tagrisso under the approved indication in korea * secondary objective: to assess efficacy of the tagrisso for patients with nsclc treated with tagrisso under the approved indication in korea.

Eligibility criteria:
* inclusion criteria: 1. eligible for, or on active study drug treatment according to the approved prescribing information; * the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations * treatment of patients with locally advanced or metastatic egfr t790m mutation-positive nsclc who have been previously treated with egfr tki therapy * the adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations 2. provision of signed and dated written informed consent by the patient or legally acceptable representative * exclusion criteria: 1. history of hypersensitivity to the active substance or to any of the excipients of this drug 2. pregnancy and/or breast feeding 3. current participation in any interventional trial
phase ii study of weekly paclitaxel (bms-181339) in patient with breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent breast cancer


Eligibility criteria:
inclusion criteria: * patients with primary advanced inoperable disease who were refractory to chemotherapy * patients with recurrent disease following post-operative adjuvant chemotherapy * patients who were not amenable to post-recurrence chemotherapy exclusion criteria: * patients with serious, uncontrolled medical illness * patients with previous therapy with taxanes
examining clinical trial participation for small cell lung cancer patients

Conditions: Small Cell Lung Cancer

Summary: clinical study participation percentages haven't always been fully representative of a given demographic. the goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through. the data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future small cell lung cancer patients during clinical trials.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed. * participant has a diagnosis of small cell lung cancer. * willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study. exclusion criteria: * patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent. * pregnant or lactating woman * known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration or interfere with the interpretation of safety results

Keywords: small cell lung cancer